166 related articles for article (PubMed ID: 21919858)
1. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
2. No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects.
Yao L; Fang F; Wu Q; Yang Z; Zhong Y; Yu L
Breast Cancer Res Treat; 2010 Jul; 122(1):221-7. PubMed ID: 20013047
[TBL] [Abstract][Full Text] [Related]
3. The UGT2B17 gene deletion is not associated with prostate cancer risk.
Olsson M; Lindström S; Häggkvist B; Adami HO; Bälter K; Stattin P; Ask B; Rane A; Ekström L; Grönberg H
Prostate; 2008 Apr; 68(5):571-5. PubMed ID: 18247404
[TBL] [Abstract][Full Text] [Related]
4. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
5. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
6. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
7. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
9. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
[TBL] [Abstract][Full Text] [Related]
10. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes.
Schulze JJ; Lorentzon M; Ohlsson C; Lundmark J; Roh HK; Rane A; Ekström L
Pharmacogenet Genomics; 2008 Jun; 18(6):477-85. PubMed ID: 18496127
[TBL] [Abstract][Full Text] [Related]
11. Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population.
Che X; Yu D; Wu Z; Zhang J; Chen Y; Han Y; Wang C; Qi J
Clin Lab; 2015; 61(12):1905-10. PubMed ID: 26882814
[TBL] [Abstract][Full Text] [Related]
12. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.
Chang B; Zheng SL; Isaacs SD; Wiley KE; Carpten JD; Hawkins GA; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB; Xu J
Int J Cancer; 2001 Nov; 95(6):354-9. PubMed ID: 11668516
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
15. Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
Song J; Tao ZH; Liu XY; Gong S; Gan L
Genet Mol Res; 2016 Feb; 15(1):15017866. PubMed ID: 26985923
[TBL] [Abstract][Full Text] [Related]
16. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.
dos Santos A; Ribeiro ML; Mesquita JC; Carvalho-Salles AB; Hackel C
Prostate Cancer Prostatic Dis; 2002; 5(1):28-31. PubMed ID: 15195127
[TBL] [Abstract][Full Text] [Related]
17. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.
Karypidis AH; Olsson M; Andersson SO; Rane A; Ekström L
Pharmacogenomics J; 2008 Apr; 8(2):147-51. PubMed ID: 17387331
[TBL] [Abstract][Full Text] [Related]
18. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
Setiawan VW; Schumacher FR; Haiman CA; Stram DO; Albanes D; Altshuler D; Berglund G; Buring J; Calle EE; Clavel-Chapelon F; Cox DG; Gaziano JM; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn J; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Ma J; Le Marchand L; Linseisen J; Lund E; Navarro C; Overvad K; Palli D; Peeters PH; Pike MC; Riboli E; Stampfer MJ; Thun MJ; Travis R; Trichopoulos D; Yeager M; Ziegler RG; Spencer Feigelson H; Chanock SJ
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2237-46. PubMed ID: 18006912
[TBL] [Abstract][Full Text] [Related]
19. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):120-6. PubMed ID: 12582021
[TBL] [Abstract][Full Text] [Related]
20. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
